Yorozu Atsunori, Toya Kazuhito, Ohashi Toshio, Ohsuga Kae, Ito Reiko, Kasamatsu Tomotaka, Saito Shiro, Momma Tetsuo
Dept. of Radiology, Tokyo Medical Center, National Hospital Organization.
Gan To Kagaku Ryoho. 2006 Apr;33(4):424-7.
This review article aims to overview modern prostate brachytherapy in Japan. Permanent transperineal prostate brachytherapy with I-125 started in September, 2003 in Japan. Brachytherapy has several advantages: the dose is adapted precisely to the tumor shape and size, and the long-lived isotope gives a higher tumor dose with less damage to normal tissue; less-time consuming for patients and staff: long-term results comparable to surgery or external beam series in the USA; and quality of life after brachytherapy also appealing. These advantages have brought about increasing use in Japan as well. Patients with a high probability of organ-confined disease and a low-risk group are appropriately treated with brachytherapy. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy. High-dose-rate (HDR) brachytherapy with Ir-192 has preceded seed implants in Japan. HDR has some theoretical advantages. Long-term results of brachytherapy in the USA are comparable with surgery or external beam irradiation so far. We should develop more sophisticated brachytherapy techniques in Japan.
这篇综述文章旨在概述日本现代前列腺近距离放射治疗。2003年9月，日本开始采用碘-125进行永久性经会阴前列腺近距离放射治疗。近距离放射治疗有几个优点：剂量能精确适应肿瘤的形状和大小，长寿命同位素能在对正常组织损伤较小的情况下给予肿瘤更高剂量；对患者和医护人员来说耗时较少；长期效果与美国的手术或外照射系列相当；近距离放射治疗后的生活质量也很有吸引力。这些优点也使得其在日本的使用越来越多。器官局限性疾病可能性高的患者和低风险组患者适合采用近距离放射治疗。有显著前列腺外扩展风险的近距离放射治疗候选患者应接受补充外照射放疗。在日本，铱-192高剂量率（HDR）近距离放射治疗先于粒子植入。HDR有一些理论上的优点。到目前为止，美国近距离放射治疗的长期效果与手术或外照射相当。我们应该在日本开发更先进的近距离放射治疗技术。
